We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases. Finding the right starting points to target diseases at their source.
Using a combination of a systematic assessment of the genetic disease landscape and informed diligence on the latest research, we find indications with clear mechanisms of pathogenesis that are ripe for translation into disease-modifying drugs.
Landos’ unique core platform technology enables accelerated development of safer, more effective oral, first-in-class therapeutics for autoimmune diseases. Landos has identified Lanthionine Synthetase C-Like 2 (LANCL2) as a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile.
MeiraGTx develops innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. We are pioneering the use of gene therapy to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). MeiraGTx is developing novel gene regulation platforms that promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
Outset Medical is focused on reimagining the experience of dialysis care for patients with kidney disease by providing them greater flexibility, independence, and control with the potential to dramatically lower cost for providers and the healthcare system.
QSpex is transforming the vision industry by combining best-in-class lens technology with an unprecedented level of service. Transforming the optical industry by offering premium prescription eyewear, fulfilled SAME-DAY, through a personalized delivery and dispensing process. Our high-speed, proprietary Rapid Lens Technology™ eliminates the pitfalls of traditional lens manufacturing. Using QSpex’s groundbreaking Touchless Transfer™ lens system, Rapid Lens Technology™ provides premium prescription eyewear through unique, covalently bonded treatments.
Renovia was formed to better diagnose, treat, and potentially improve the lives of millions of women through a platform of innovative sensor technologies combined with a digital health platform. This allows precise, cost-effective visualization and treatment of weakened pelvic floor muscles in real time, while collecting actionable compliance and progress data on women’s pelvic health. Restoring pelvic health by strengthening pelvic floor muscles through clinically benefiting solutions is paramount to treating the underlying causes of Pelvic Floor Disorders.
A private company focused on acquiring and developing disease modifying therapies for Duchenne Muscular Dystrophy through rigorous scientific analysis, efficient capital management and global collaborations.
Tivorsan Pharmaceuticals is a protein therapeutics company pioneering a unique approach to treat serious neuromuscular disorders, including Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD).
Vapotherm is dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery cost and improve quality of life for patients. Vapotherm High Flow Therapy provides support for patients in respiratory distress and has been used in over half a million patients.
Vensun Pharmaceuticals is an emerging generic pharmaceutical company developing a portfolio of difficult to access or hard to formulate generic prescription products.
Verrica Pharmaceuticals is a clinical-stage pharmaceutical company developing proprietary topical therapies for the treatment of skin diseases such as Verruca vulgaris (common warts and plantar warts) and Molluscum contagiosum. Current treatments for these and similar conditions have only limited efficacy, are painful or require daily compliance for an extended treatment period to see results.
Vitruvias is a specialty generic pharmaceutical business focused on the development and marketing of generic products with either (i) complex APIs that are difficult to source, or (ii) finished dosage forms that are inherently difficult to manufacture. The highly skilled team at Vitruvias has expertise in all aspects of the pharmaceutical industry, including product development, licensing, regulatory affairs, marketing, financial analysis, distribution, managed care, trade relations and sales.
Vyome Biosciences is an innovation driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development.
Xontogeny (zon-TOJ-uh-nee) is a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases. Speciﬁcally, we partner with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development.